{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:55:42Z","timestamp":1791813342360,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0132-6","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T03:01:13Z","timestamp":1429585273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway"],"prefix":"10.1186","volume":"8","author":[{"given":"Bill H","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"LaTocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle S J","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Loriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00fcschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"132_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"CH Pui","year":"2013","unstructured":"Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50:185\u201396.","journal-title":"Semin Hematol"},{"key":"132_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005\u201315.","journal-title":"N Engl J Med"},{"key":"132_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc2293","volume":"8","author":"DC Altieri","year":"2008","unstructured":"Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61\u201370.","journal-title":"Nat Rev Cancer"},{"key":"132_CR4","first-page":"447","volume":"5","author":"DC Altieri","year":"2003","unstructured":"Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res. 2003;5:447\u201352.","journal-title":"Prog Cell Cycle Res"},{"key":"132_CR5","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood.V100.7.2463","volume":"100","author":"S Fukuda","year":"2002","unstructured":"Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood. 2002;100:2463\u201371.","journal-title":"Blood"},{"key":"132_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/hupa.2001.21897","volume":"32","author":"R Gianani","year":"2001","unstructured":"Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119\u201325.","journal-title":"Hum Pathol"},{"key":"132_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2008-11-188714","volume":"114","author":"S Fukuda","year":"2009","unstructured":"Fukuda S, Singh P, Moh A, Abe M, Conway EM, Boswell HS, et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood. 2009;114:394\u2013403.","journal-title":"Blood"},{"key":"132_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3324\/haematol.10675","volume":"92","author":"A Troeger","year":"2007","unstructured":"Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 2007;92:1043\u201350.","journal-title":"Haematologica"},{"key":"132_CR9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1182\/blood-2011-04-351239","volume":"118","author":"E Park","year":"2011","unstructured":"Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011;118:2191\u20139.","journal-title":"Blood"},{"key":"132_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/leu.2011.199","volume":"26","author":"DJ Morrison","year":"2012","unstructured":"Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012;26:271\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"132_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MPH.0b013e3182a8f58f","volume":"36","author":"EA Raetz","year":"2014","unstructured":"Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014;36(6):458\u201363.","journal-title":"J Pediatr Hematol Oncol"},{"key":"132_CR12","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","volume":"67","author":"T Nakahara","year":"2007","unstructured":"Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67:8014\u201321.","journal-title":"Cancer Res"},{"key":"132_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","volume":"102","author":"T Nakahara","year":"2011","unstructured":"Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011;102:614\u201321.","journal-title":"Cancer Sci"},{"issue":"4","key":"132_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/leu.2011.249","volume":"26","author":"JW Tyner","year":"2012","unstructured":"Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 2012;26(4):623\u201332.","journal-title":"Leukemia"},{"key":"132_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00280-012-1868-0","volume":"70","author":"TG Glaros","year":"2012","unstructured":"Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL. The \u201csurvivin suppressants\u201d NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012;70:207\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"132_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.113.204743","volume":"346","author":"DR Premkumar","year":"2013","unstructured":"Premkumar DR, Jane EP, Foster KA, Pollack IF. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther. 2013;346:201\u201310.","journal-title":"J Pharmacol Exp Ther"},{"key":"132_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbrc.2013.04.036","volume":"435","author":"W Feng","year":"2013","unstructured":"Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013;435:52\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"132_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nchembio.1590","volume":"10","author":"GE Winter","year":"2014","unstructured":"Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014;10:768\u201373.","journal-title":"Nat Chem Biol"},{"key":"132_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","volume":"73","author":"JW Tyner","year":"2013","unstructured":"Tyner JW, Yang WF, Bankhead 3rd A, Fan G, Fletcher LB, Bryant J, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73:285\u201396.","journal-title":"Cancer Res"},{"issue":"Pt 2","key":"132_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/0264-6021:3440305","volume":"344","author":"F Li","year":"1999","unstructured":"Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344(Pt 2):305\u201311.","journal-title":"Biochem J"},{"key":"132_CR21","first-page":"179","volume":"3","author":"Q Cheng","year":"2012","unstructured":"Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012;3:179\u201397.","journal-title":"Int J Biochem Mol Biol"},{"key":"132_CR22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bcp.2011.07.064","volume":"82","author":"H Tang","year":"2011","unstructured":"Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol. 2011;82:1066\u201372.","journal-title":"Biochem Pharmacol"},{"key":"132_CR23","doi-asserted-by":"crossref","first-page":"24385","DOI":"10.1016\/S0021-9258(20)80537-7","volume":"268","author":"MC Hollander","year":"1993","unstructured":"Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace Jr AJ. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem. 1993;268:24385\u201393.","journal-title":"J Biol Chem"},{"key":"132_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.tcb.2004.05.001","volume":"14","author":"CJ Bakkenist","year":"2004","unstructured":"Bakkenist CJ, Kastan MB. Phosphatases join kinases in DNA-damage response pathways. Trends Cell Biol. 2004;14:339\u201341.","journal-title":"Trends Cell Biol"},{"key":"132_CR25","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nprot.2008.93","volume":"3","author":"A Muslimovic","year":"2008","unstructured":"Muslimovic A, Ismail IH, Gao Y, Hammarsten O. An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells. Nat Protoc. 2008;3:1187\u201393.","journal-title":"Nat Protoc"},{"key":"132_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/1471-2407-12-619","volume":"12","author":"YF Tao","year":"2012","unstructured":"Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 2012;12:619.","journal-title":"BMC Cancer"},{"key":"132_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/jpet.102.037192","volume":"303","author":"M Zhou","year":"2002","unstructured":"Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther. 2002;303:124\u201331.","journal-title":"J Pharmacol Exp Ther"},{"key":"132_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-014-0062-8","volume":"7","author":"Q Qin","year":"2014","unstructured":"Qin Q, Cheng H, Lu J, Zhan L, Zheng J, Cai J, et al. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair. J Hematol Oncol. 2014;7:62.","journal-title":"J Hematol Oncol"},{"key":"132_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/pbc.20635","volume":"47","author":"M Baudis","year":"2006","unstructured":"Baudis M, Prima V, Tung YH, Hunger SP. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer. 2006;47:757\u201364.","journal-title":"Pediatr Blood Cancer"},{"key":"132_CR30","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","volume":"15","author":"T Satoh","year":"2009","unstructured":"Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3872\u201380.","journal-title":"Clin Cancer Res"},{"key":"132_CR31","first-page":"202","volume":"1845","author":"A Rauch","year":"2014","unstructured":"Rauch A, Hennig D, Schafer C, Wirth M, Marx C, Heinzel T, et al. Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta. 2014;1845:202\u201320.","journal-title":"Biochim Biophys Acta"},{"key":"132_CR32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/nprot.2006.353","volume":"1","author":"V Azuara","year":"2006","unstructured":"Azuara V. Profiling of DNA replication timing in unsynchronized cell populations. Nat Protoc. 2006;1:2171\u20137.","journal-title":"Nat Protoc"},{"key":"132_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","volume":"2","author":"BM Gyori","year":"2014","unstructured":"Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement MV. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014;2:457\u201365.","journal-title":"Redox Biol"},{"key":"132_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/0024-3205(89)90148-3","volume":"45","author":"RJ Tallarida","year":"1989","unstructured":"Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 1989;45:947\u201361.","journal-title":"Life Sci"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-015-0132-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0132-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:13:33Z","timestamp":1651767213000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-015-0132-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0132-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]},"assertion":[{"value":"30 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}